As suggested by a growing number of recent studies, clinical treatment of CRC may be facilitated by increasing intracellular Fe2+ and ROS, decreasing GSH levels in CRC cells or inactivating GPX4. The gene discussed is GPX4; the disease is colorectal carcinoma.